Article
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.
Cancer immunology, immunotherapy : CII - 1 Mar 2021
Anghileri Elena, Di Ianni Natalia, Paterra Rosina, Langella Tiziana, Zhao Junfei, Eoli Marica, Patanè Monica, Pollo Bianca, Cuccarini Valeria, Iavarone Antonio, Rabadan Raul, Finocchiaro Gaetano, Pellegatta Serena
Abstract excerpt
BACKGROUND: Glioblastomas (GBMs) in patients harboring somatic or germinal mutations of mismatch-repair (MMR) genes exhibit a hypermutable phenotype. Here, we describe a GBM patient with increased tumor mutational burden and germline MMR mutations, treated using anti-PD1 therapy. METHODS: A woman with newly diagnosed GBM (nGBM) was treated by surgery, radiotherapy, and temozolomide. The tumor recurred after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.